Jul. 11 at 3:03 AM
$ABCL
By 2032, AbCellera could have advanced somewhere around ~10-16 molecules in-house (1-2 new molecules/yr on average)
The two new molecules for 2027 are expected to be of comparable value and differentiation to that of ABCL635 (for reference, 635 is first in class / ~
$6B TAM, although not all of that TAM will be captured).
They’re committed to staying “on brand” with differentiated assets with high technical barriers to entry. If they continue to target similar or greater value to that of 635, I think things could be pretty exciting come 2030-2035 era depending on how many molecules make it to ph2 or 3 by then.
Hopefully 635 will be a success and set the tone for the market to recognize what the company is capable of delivering.
And that’s not including partnership programs such as new TCE deals or their existing partnership deals.
